IL17A and psoriasis: In recent years, the introduction of biologic therapies targeting specific disease pathways, such as tumor necrosis factor α (TNF-α) and IL-17 and IL-23 inhibitors, represents a significant progress in the treatment of moderate-to-severe psoriasis [1,9].